Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Inc (NQ: PRLD )

3.770 -0.070 (-1.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 48,436
Open 3.840
Bid (Size) 3.400 (3)
Ask (Size) 3.980 (1)
Prev. Close 3.840
Today's Range 3.560 - 3.860
52wk Range 1.660 - 6.890
Shares Outstanding 54,808,715
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitor 
From Prelude Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-7.37%
-7.37%
1 Month
-19.62%
-19.62%
3 Month
+4.72%
+4.72%
6 Month
+112.99%
+112.99%
1 Year
-38.80%
-38.80%

More News

Read More
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
Via Benzinga
The Latest Analyst Ratings for Prelude Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
From Prelude Therapeutics, Inc.
Via GlobeNewswire
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Prelude Therapeutics Announces $25 Million Private Placement
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.